von Tobias Borgers | Aug. 26, 2019 | Roche
Media Release Basel, 14 May 2019 Roche and Spark Therapeutics, Inc. announce expected refiling date of Premerger Notification and Report Forms under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc. Parties elect to refile Premerger...
von Tobias Borgers | Aug. 24, 2019 | Roche
Media Release Basel, 16 May 2019 Roche’s personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents Phase I/II study of entrectinib, an investigational medicine, showed responses in all paediatric tumour...
von Tobias Borgers | Aug. 24, 2019 | MSD
Pressemitteilung Elimination von Gebärmutterhalskrebs könnte innerhalb dieses Jahrhunderts möglich sein Haar, 18. April 2019 Gebärmutterhalskrebs könnte schon am Ende dieses Jahrhunderts in den meisten Ländern der Welt unter eine mögliche Eliminierungsschwelle fallen....
von Tobias Borgers | Aug. 24, 2019 | Novartis
Imagine you are born already facing a number of setbacks in life. Imagine you lose out on the health benefits of breastfeeding when you are an infant, because you are the sixth child in the family and your mother has to work because she is struggling to make ends...
von Tobias Borgers | Aug. 24, 2019 | Glaxo
Issued: London UK GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive headline results from the pivotal DREAMM-2 open-label, randomised study of two doses of belantamab mafodotin (GSK2857916). The 196 patients in the trial had relapsed multiple myeloma, were...
